Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1994 Aug;3(8):1159–1168. doi: 10.1002/pro.5560030802

The pharmacophore of the human C5a anaphylatoxin.

M J Toth 1, L Huwyler 1, W C Boyar 1, A F Braunwalder 1, D Yarwood 1, J Hadala 1, W O Haston 1, M A Sills 1, B Seligmann 1, N Galakatos 1
PMCID: PMC2142918  PMID: 7987211

Abstract

We have determined which amino acids contribute to the pharmacophore of human C5a, a potent inflammatory mediator. A systematic mutational analysis of this 74-amino acid protein was performed and the effects on the potency of receptor binding and of C5a-induced intracellular calcium ion mobilization were measured. This analysis included the construction of hybrids between C5a and the homologous but unreactive C3a protein and site-directed mutagenesis. Ten noncontiguous amino acids from the structurally well-defined 4-helix core domain (amino acids 1-63) and the C-terminal arginine-containing tripeptide were found to contribute to the pharmacophore of human C5a. The 10 mostly charged amino acids from the core domain generally made small incremental contributions toward binding affinity, some of which were independent. Substitutions of the C-terminal amino acid Arg 74 produced the largest single effect. We also found the connection between these 2 important regions to be unconstrained.

Full Text

The Full Text of this article is available as a PDF (2.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braunwalder A. F., Musmanno D., Galakatos N., Garlick R. H., Haston W. O., Rediske J. J., Wennogle L., Seligmann B., Sills M. A. Characterization of the binding of Bolton-Hunter labeled [125I]C5a to human neutrophil, monocyte and U-937 cell membranes. Mol Immunol. 1992 Nov;29(11):1319–1324. doi: 10.1016/0161-5890(92)90168-w. [DOI] [PubMed] [Google Scholar]
  2. Carney D. F., Hugli T. E. Site-specific mutations in the N-terminal region of human C5a that affect interactions of C5a with the neutrophil C5a receptor. Protein Sci. 1993 Sep;2(9):1391–1399. doi: 10.1002/pro.5560020904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carter P., Wells J. A. Dissecting the catalytic triad of a serine protease. Nature. 1988 Apr 7;332(6164):564–568. doi: 10.1038/332564a0. [DOI] [PubMed] [Google Scholar]
  4. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  5. Chenoweth D. E., Hugli T. E. Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol Immunol. 1980 Feb;17(2):151–161. doi: 10.1016/0161-5890(80)90067-x. [DOI] [PubMed] [Google Scholar]
  6. Crawford M. H., Grover F. L., Kolb W. P., McMahan C. A., O'Rourke R. A., McManus L. M., Pinckard R. N. Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation. 1988 Dec;78(6):1449–1458. doi: 10.1161/01.cir.78.6.1449. [DOI] [PubMed] [Google Scholar]
  7. Cunningham B. C., Jhurani P., Ng P., Wells J. A. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science. 1989 Mar 10;243(4896):1330–1336. doi: 10.1126/science.2466339. [DOI] [PubMed] [Google Scholar]
  8. Franke A. E., Andrews G. C., Stimler-Gerard N. P., Gerard C. J., Showell H. J. Human C5a anaphylatoxin: gene synthesis, expression, and recovery of biologically active material from Escherichia coli. Methods Enzymol. 1988;162:653–668. doi: 10.1016/0076-6879(88)62107-0. [DOI] [PubMed] [Google Scholar]
  9. Hugli T. E., Müller-Eberhard H. J. Anaphylatoxins: C3a and C5a. Adv Immunol. 1978;26:1–53. doi: 10.1016/s0065-2776(08)60228-x. [DOI] [PubMed] [Google Scholar]
  10. Kawai M., Quincy D. A., Lane B., Mollison K. W., Or Y. S., Luly J. R., Carter G. W. Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a. J Med Chem. 1992 Jan 24;35(2):220–223. doi: 10.1021/jm00080a004. [DOI] [PubMed] [Google Scholar]
  11. Mandecki W., Mollison K. W., Bolling T. J., Powell B. S., Carter G. W., Fox J. L. Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3543–3547. doi: 10.1073/pnas.82.11.3543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Miller J. J., 3rd, Olds L. C., Huene D. B. Complement activation products and factors influencing phagocyte migration in synovial fluids from children with chronic arthritis. Clin Exp Rheumatol. 1986 Jan-Mar;4(1):53–56. [PubMed] [Google Scholar]
  13. Mollison K. W., Fey T. A., Krause R. A., Miller L., Edalji R. P., Conway R. G., Mandecki W., Shallcross M. A., Kawai M., Or Y. S. C5a structural requirements for neutrophil receptor interaction. Agents Actions Suppl. 1991;35:17–21. [PubMed] [Google Scholar]
  14. Mollison K. W., Mandecki W., Zuiderweg E. R., Fayer L., Fey T. A., Krause R. A., Conway R. G., Miller L., Edalji R. P., Shallcross M. A. Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc Natl Acad Sci U S A. 1989 Jan;86(1):292–296. doi: 10.1073/pnas.86.1.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Morgan E. L., Ember J. A., Sanderson S. D., Scholz W., Buchner R., Ye R. D., Hugli T. E. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor. J Immunol. 1993 Jul 1;151(1):377–388. [PubMed] [Google Scholar]
  16. Or Y. S., Clark R. F., Lane B., Mollison K. W., Carter G. W., Luly J. R. Improvements in the minimum binding sequence of C5a: examination of His-67. J Med Chem. 1992 Jan 24;35(2):402–406. doi: 10.1021/jm00080a030. [DOI] [PubMed] [Google Scholar]
  17. Ozaki T., Hayashi H., Tani K., Ogushi F., Yasuoka S., Ogura T. Neutrophil chemotactic factors in the respiratory tract of patients with chronic airway diseases or idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1992 Jan;145(1):85–91. doi: 10.1164/ajrccm/145.1.85. [DOI] [PubMed] [Google Scholar]
  18. Robbins R. A., Russ W. D., Rasmussen J. K., Clayton M. M. Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis. 1987 Mar;135(3):651–658. doi: 10.1164/arrd.1987.135.3.651. [DOI] [PubMed] [Google Scholar]
  19. Schröder J. M., Gregory H., Young J., Christophers E. Neutrophil-activating proteins in psoriasis. J Invest Dermatol. 1992 Feb;98(2):241–247. doi: 10.1111/1523-1747.ep12556058. [DOI] [PubMed] [Google Scholar]
  20. Seligmann B., Patel K., Haston W. O., Rediske J. J. Fluorometer based multi-parameter analysis of phagocytic cell activation. Agents Actions. 1987 Aug;21(3-4):375–378. doi: 10.1007/BF01966520. [DOI] [PubMed] [Google Scholar]
  21. Swerlick R. A., Yancey K. B., Lawley T. J. A direct in vivo comparison of the inflammatory properties of human C5a and C5a des Arg in human skin. J Immunol. 1988 Apr 1;140(7):2376–2381. [PubMed] [Google Scholar]
  22. Toth M. J., Schimmel P. A mutation in the small (alpha) subunit of glycyl-tRNA synthetase affects amino acid activation and subunit association parameters. J Biol Chem. 1990 Jan 15;265(2):1005–1009. [PubMed] [Google Scholar]
  23. Weisman H. F., Bartow T., Leppo M. K., Marsh H. C., Jr, Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990 Jul 13;249(4965):146–151. doi: 10.1126/science.2371562. [DOI] [PubMed] [Google Scholar]
  24. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 1990 Sep 18;29(37):8509–8517. doi: 10.1021/bi00489a001. [DOI] [PubMed] [Google Scholar]
  25. Yoshizawa Y., Nomura A., Ohdama S., Tanaka M., Morinari H., Hasegawa S. The significance of complement activation in the pathogenesis of hypersensitivity pneumonitis: sequential changes of complement components and chemotactic activities in bronchoalveolar lavage fluids. Int Arch Allergy Appl Immunol. 1988;87(4):417–423. doi: 10.1159/000234712. [DOI] [PubMed] [Google Scholar]
  26. Zuiderweg E. R., Nettesheim D. G., Mollison K. W., Carter G. W. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data. Biochemistry. 1989 Jan 10;28(1):172–185. doi: 10.1021/bi00427a025. [DOI] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES